Targeted Therapy for Leukemia
白血病靶向治疗
基本信息
- 批准号:10251287
- 负责人:
- 金额:$ 97.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAreaBiologicalChronic Lymphocytic LeukemiaCollaborationsDataDiseaseDisease modelDisease remissionDrug Delivery SystemsGeneticGenetic studyHematologic NeoplasmsHematopoietic NeoplasmsImmune ToleranceImmunotherapyInvestigationKnowledgeLaboratoriesLaboratory ResearchMethodsPathway interactionsPatientsPrimary NeoplasmProteomicsResearchResearch PersonnelSamplingTechniquesTranslatingWorkadult leukemiaclinical applicationclinically relevantcurative treatmentshuman diseaseimmunoregulationleukemiamouse modelnext generation sequencingnovelnovel therapeuticsprogramspublic health relevancerecruittargeted treatmenttherapeutic developmenttherapeutic targettumor
项目摘要
DESCRIPTION (provided by applicant): The Byrd translational laboratory research program focuses on basic and translational biologic questions to develop novel immunologic and targeted therapies for hematologic malignancies. Chronic lymphocytic leukemia (CLL) is utilized as our disease model as it allows integration of mechanistic and genetic studies in spontaneous leukemia mouse models with studies using primary tumor samples, thereby enhancing the clinical relevance of our findings. Our highly collaborative laboratory team works to identify, dissect, and solve challenges in leukemia therapeutic development that capitalizes on the strengths of each to drive projects to clinical application. It also allows us to exploit diverse techniques (e.g. proteomics, next-generation sequencing) and embark on new areas (e.g. novel drug delivery methods, target identification, introduction of new animal models) to translate our findings across multiple human diseases. This strategy has resulted in powerful collaborations, recruiting skilled researchers from other fields to apply their knowledge to leukemia. I envision the greatest impact from my research will come from integrating therapeutics that target tumor survival pathways with agents that reverse immune tolerance to facilitate long-term remissions or cure. My work to date has resulted in the approval of two agents for CLL therapy that prolong survival. Our ongoing work with imbrutinib dispels a commonly held paradigm that it is not possible to develop a general "disease-targeted therapy" when a specific genetic aberration is not present. My hypothesis is that general disease-targeted therapy requires dual tumor-targeted and immunologic modulation. I seek to aggressively develop this concept and extend it to other areas as our data directs us.
描述(由申请人提供):伯德转化实验室研究计划的重点是基础和转化生物学问题,以开发新的免疫和靶向治疗血液恶性肿瘤。慢性淋巴细胞白血病(CLL)被用作我们的疾病模型,因为它允许将自发性白血病小鼠模型中的机制和遗传研究与使用原发性肿瘤样本的研究相结合,从而增强我们发现的临床相关性。我们高度协作的实验室团队致力于识别、剖析和解决白血病治疗开发中的挑战,充分利用各自的优势,推动项目走向临床应用。它还使我们能够利用不同的技术(例如蛋白质组学,下一代测序),并开始新的领域(例如新型药物递送方法,靶标识别,引入新的动物模型),以将我们的发现转化为多种人类疾病。这一策略导致了强大的合作,从其他领域招募熟练的研究人员,将他们的知识应用于白血病。我设想我的研究的最大影响将来自于将针对肿瘤生存途径的治疗方法与逆转免疫耐受以促进长期缓解或治愈的药物相结合。迄今为止,我的工作已经批准了两种用于CLL治疗的药物,可以延长生存期。我们正在进行的伊马替尼研究消除了一种普遍持有的范式,即当不存在特定的遗传畸变时,不可能开发出通用的“疾病靶向治疗”。我的假设是,一般的疾病靶向治疗需要双重肿瘤靶向和免疫调节。我寻求积极发展这一概念,并根据我们的数据指导我们将其扩展到其他领域。
项目成果
期刊论文数量(56)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts.
- DOI:10.1093/nargab/lqaa070
- 发表时间:2020-12
- 期刊:
- 影响因子:4.6
- 作者:Gregory T;Ngankeu A;Orwick S;Kautto EA;Woyach JA;Byrd JC;Blachly JS
- 通讯作者:Blachly JS
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
- DOI:10.1158/2326-6066.cir-15-0291
- 发表时间:2016-08
- 期刊:
- 影响因子:10.1
- 作者:Browning RL;Byrd WH;Gupta N;Jones J;Mo X;Hertlein E;Yu L;Muthusamy N;Byrd JC
- 通讯作者:Byrd JC
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
- DOI:10.3324/haematol.2021.278901
- 发表时间:2022-06-01
- 期刊:
- 影响因子:10.1
- 作者:Brown, Jennifer R.;Byrd, John C.;Ghia, Paolo;Sharman, Jeff P.;Hillmen, Peter;Stephens, Deborah M.;Sun, Clare;Jurczak, Wojciech;Pagel, John M.;Ferrajoli, Alessandra;Patel, Priti;Tao, Lin;Kuptsova-Clarkson, Nataliya;Moslehi, Javid;Furman, Richard R.
- 通讯作者:Furman, Richard R.
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
在先前治疗的慢性淋巴细胞性白血病中,阿卡劳替尼与伊布鲁替尼:第一次随机III期试验的结果。
- DOI:10.1200/jco.21.01210
- 发表时间:2021-11-01
- 期刊:
- 影响因子:0
- 作者:Byrd JC;Hillmen P;Ghia P;Kater AP;Chanan-Khan A;Furman RR;O'Brien S;Yenerel MN;Illés A;Kay N;Garcia-Marco JA;Mato A;Pinilla-Ibarz J;Seymour JF;Lepretre S;Stilgenbauer S;Robak T;Rothbaum W;Izumi R;Hamdy A;Patel P;Higgins K;Sohoni S;Jurczak W
- 通讯作者:Jurczak W
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
- DOI:10.3324/haematol.2017.171041
- 发表时间:2017-10
- 期刊:
- 影响因子:10.1
- 作者:Brown JR;Moslehi J;O'Brien S;Ghia P;Hillmen P;Cymbalista F;Shanafelt TD;Fraser G;Rule S;Kipps TJ;Coutre S;Dilhuydy MS;Cramer P;Tedeschi A;Jaeger U;Dreyling M;Byrd JC;Howes A;Todd M;Vermeulen J;James DF;Clow F;Styles L;Valentino R;Wildgust M;Mahler M;Burger JA
- 通讯作者:Burger JA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN C. BYRD其他文献
JOHN C. BYRD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN C. BYRD', 18)}}的其他基金
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies
ITSC 治疗白血病:NCTN“个体化”治疗的新型分子策略
- 批准号:
9906201 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies
ITSC 治疗白血病:NCTN“个体化”治疗的新型分子策略
- 批准号:
10372019 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies
ITSC 治疗白血病:NCTN“个体化”治疗的新型分子策略
- 批准号:
10512808 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
Dual targeting of XPO1 and BTK in B cell malignancies
B 细胞恶性肿瘤中 XPO1 和 BTK 的双重靶向
- 批准号:
9259981 - 财政年份:2015
- 资助金额:
$ 97.12万 - 项目类别:
OSU as Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
- 批准号:
8605679 - 财政年份:2014
- 资助金额:
$ 97.12万 - 项目类别:
相似国自然基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
- 批准号:2021JJ40433
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
- 批准号:32001603
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
AREA国际经济模型的移植.改进和应用
- 批准号:18870435
- 批准年份:1988
- 资助金额:2.0 万元
- 项目类别:面上项目
相似海外基金
Tribal Intertidal Digital Ecological Surveys Project: Using Large-Area Imaging to Assess Intertidal Biological Response to Changing Oceanographic Conditions in Partnership with Indigenous Nations
部落潮间带数字生态调查项目:与土著民族合作,利用大面积成像评估潮间带生物对不断变化的海洋条件的反应
- 批准号:
532685-2019 - 财政年份:2022
- 资助金额:
$ 97.12万 - 项目类别:
Postgraduate Scholarships - Doctoral
Tribal Intertidal Digital Ecological Surveys Project: Using Large-Area Imaging to Assess Intertidal Biological Response to Changing Oceanographic Conditions in Partnership with Indigenous Nations
部落潮间带数字生态调查项目:与土著民族合作,利用大面积成像评估潮间带生物对不断变化的海洋条件的反应
- 批准号:
532685-2019 - 财政年份:2020
- 资助金额:
$ 97.12万 - 项目类别:
Postgraduate Scholarships - Doctoral
biological interactions among forest-dwelling fungus gnats and their natural enemies in shiitake mashroom production area
香菇产区森林真菌蚊与其天敌之间的生物相互作用
- 批准号:
19K06152 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tribal Intertidal Digital Ecological Surveys Project: Using Large-Area Imaging to Assess Intertidal Biological Response to Changing Oceanographic Conditions in Partnership with Indigenous Nations
部落潮间带数字生态调查项目:与土著民族合作,利用大面积成像评估潮间带生物对不断变化的海洋条件的反应
- 批准号:
532685-2019 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
Postgraduate Scholarships - Doctoral
To what extent does governance play a role in how effectively a marine protected area in the Irish Sea reaches its biological and socioeconomic goals?
治理在多大程度上对爱尔兰海海洋保护区如何有效实现其生物和社会经济目标发挥作用?
- 批准号:
2287487 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
Studentship
War and Biological Ageing in Vietnam: A Planning Grant to Foster Collaboration on a Novel Area of Global Research in Health and Ageing
越南的战争与生物衰老:一项规划拨款,以促进全球健康与老龄化研究新领域的合作
- 批准号:
404425 - 财政年份:2019
- 资助金额:
$ 97.12万 - 项目类别:
Miscellaneous Programs
Impact assessment of Noctiluca scintillans red tide on nutrient dynamics, biological processes in lower trophic levels and material cycle in the neritic area of Sagami Bay
夜光藻赤潮对相模湾浅海区营养动态、低营养层生物过程和物质循环的影响评估
- 批准号:
18K05794 - 财政年份:2018
- 资助金额:
$ 97.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Large-area graphene based chemical and biological sensors
基于大面积石墨烯的化学和生物传感器
- 批准号:
355863-2011 - 财政年份:2015
- 资助金额:
$ 97.12万 - 项目类别:
Discovery Grants Program - Individual
Large-area graphene based chemical and biological sensors
基于大面积石墨烯的化学和生物传感器
- 批准号:
355863-2011 - 财政年份:2014
- 资助金额:
$ 97.12万 - 项目类别:
Discovery Grants Program - Individual
Theoretical simulation and experimental study on biological weathering mechanism of the rock around coastal area in Yaeyama Islands
八重山群岛沿岸岩石生物风化机制的理论模拟与实验研究
- 批准号:
26790079 - 财政年份:2014
- 资助金额:
$ 97.12万 - 项目类别:
Grant-in-Aid for Young Scientists (B)